The Swiss drugmaker announced its biggest deal in a decade on Sunday, as its set to buy Avidity Biosciences for about $12 billion. "We have adequate firepower to do deals like this and to bolster the ...

Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation." ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

LONDON (Reuters) -Swiss drugmaker Novartis on Monday defended its $12 billion deal to acquire Avidity Biosciences ahead of the U.S. firm getting late-stage data for its muscle disorder treatment next ...

GENEVA (AP) — Novartis CEO Joseph Jimenez will step down early next year and be replaced by fellow American Dr. Vasant Narasimhan, the Swiss pharmaceutical company said Monday. Narasimhan, currently ...

Stream NBC 5 for free, 24/7, wherever you are. The CEO of Novartis said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the "frenzy" of weight loss drugs, preferring instead ...

Yesterday, the MS/MBA program at Harvard Business School (HBS) hosted Novartis CEO Dr. Vas Narasimhan for what proved to be a captivating and wide-ranging discussion, led by Dr. Christiana Bardon ...

ZURICH (Reuters) - Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for ...

Novartis CEO Dr. Vasant Narasimhan joins 'Mad Money' host Jim Cramer to talk its product pipeline, vaccine development, utilizing AI, and more. Got a confidential news tip? We want to hear from you.